+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Respiratory Syncytial Virus Vaccine"

RSV preF vaccine - Product Thumbnail Image

RSV preF vaccine

  • Report
  • October 2018
  • 15 Pages
  • Global
From
Synagis - Product Thumbnail Image

Synagis

  • Report
  • October 2018
  • 20 Pages
  • Global
From
MVA-BN RSV - Product Thumbnail Image

MVA-BN RSV

  • Report
  • October 2018
  • 18 Pages
  • Global
From
ChAd155-RSV - Product Thumbnail Image

ChAd155-RSV

  • Report
  • October 2018
  • 15 Pages
  • Global
From
GSK-3003891A - Product Thumbnail Image

GSK-3003891A

  • Report
  • October 2018
  • 15 Pages
  • Global
From
From
Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028 - Product Thumbnail Image

Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028

  • Report
  • November 2019
  • 153 Pages
  • Asia Pacific
From
From
From
RSV F Vaccine - Product Thumbnail Image

RSV F Vaccine

  • Report
  • October 2018
  • 21 Pages
  • Global
From
Loading Indicator

The Respiratory Syncytial Virus (RSV) Vaccine is a type of respiratory drug used to prevent infection from the RSV virus. It is typically administered to infants and young children, as well as to adults who are at high risk of developing severe RSV infection. The vaccine works by stimulating the body’s immune system to produce antibodies that can fight off the virus. It is usually given in two doses, with the second dose given one month after the first. The RSV Vaccine market is a growing sector of the respiratory drugs market. It is estimated that the global RSV Vaccine market will reach a value of over $1 billion by 2025. The market is driven by increasing awareness of the virus and its potential to cause severe illness, as well as the development of new vaccines. Some of the major companies in the RSV Vaccine market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novavax. Show Less Read more